Search Result

Results for "

bone-targeted

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Drug Intermediate (1) EGFR (1) Liposome (4) Notch (1) Phosphatase (1) Radionuclide-Drug Conjugates (RDCs) (3) Src (1) γ-secretase (1)
By Research Areas:	Cancer (8) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108786

Asfotase alfa ENB-0040	Phosphatase	Metabolic Disease
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ^/ knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .

HY-W008951

Ethylenediaminetetra(methylenephosphonic acid) EDTMP	Radionuclide-Drug Conjugates (RDCs)	Neurological Disease Cancer
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .

HY-139564

DOTA Zoledronate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .

HY-107093

MBC-11	Apoptosis	Cancer
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research .

HY-125064

AP22408	Src	Cancer
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC₅₀ value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-145428

BT-GSI	Notch γ-secretase	Cancer
BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression .

HY-107093B

MBC-11 triethylamine	Apoptosis	Cancer
MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research .

HY-107093A

MBC-11 trisodium	Apoptosis	Cancer
MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research .

HY-W008951A

Ethylenediaminetetra(methylenephosphonic acid) sodium EDTMP sodium	Radionuclide-Drug Conjugates (RDCs)	Neurological Disease Cancer
Ethylenediaminetetramethylenephosphonic acid (EDTMP) sodium is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid sodium is used to study palliative therapy for pain associated with multiple bone metastatic cancers .

HY-159701A

DBCO-PEG2000-Alendronic acid sodium	Drug Intermediate	Others
DBCO-PEG2000-alendronic acid sodium is a PEG linker conjugated with alendronic acid (HY-B0631) and DBCO groups. Alendronic acid possesses bone-targeting properties, enabling strong chelation with calcium ions in bone and hydroxyapatite, and exhibits high specific adsorption on mineralized tissues such as bones and teeth. This compound can be applied to construct bone-targeted drug delivery systems and bone tissue imaging probes.

HY-182092

DSPE-PEG1000-Asp6	Liposome	Others
DSPE-PEG1000-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG1000-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

HY-182092A

DSPE-PEG5000-Asp6	Liposome	Others
DSPE-PEG5000-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG5000-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

HY-182092C

DSPE-PEG3400-Asp6	Liposome	Others
DSPE-PEG3400-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG3400-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

HY-182092B

DSPE-PEG2000-Asp6	Liposome	Others
DSPE-PEG2000-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG2000-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

Cat. No.	Product Name	Type

HY-W008951

Ethylenediaminetetra(methylenephosphonic acid) EDTMP	Biochemical Assay Reagents
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .

Ethylenediaminetetra(methylenephosphonic acid)

EDTMP

Biochemical Assay Reagents

Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .

HY-182092

DSPE-PEG1000-Asp6	Biochemical Assay Reagents
DSPE-PEG1000-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG1000-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

HY-182092A

DSPE-PEG5000-Asp6	Biochemical Assay Reagents
DSPE-PEG5000-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG5000-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

HY-182092C

DSPE-PEG3400-Asp6	Biochemical Assay Reagents
DSPE-PEG3400-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG3400-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

HY-182092B

DSPE-PEG2000-Asp6	Biochemical Assay Reagents
DSPE-PEG2000-Asp6 is a PEG compound which composed of DSPE and a Asp6 peptide. DSPE-PEG2000-Asp6 achieves bone-targeted delivery of drugs or imaging agents by binding to bone tissue with the Asp6 peptide through high affinity .

Cat. No.	Product Name	Target	Research Area

HY-P11070

SDSSD	Peptides	Others
SDSSD is an osteoblast-targeting peptide. SDSSD selectively binds to periostin on osteoblasts and mediates targeted delivery to these cells. SDSSD can endow calcium phosphate nanocomposites with bone-targeting properties, and these materials exhibit osteointegrative capacity in both in vitro and in vivo models. When conjugated with polyurethane nanomicelles, SDSSD enables targeted delivery of siRNA/microRNA to osteoblasts .

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-P11552

(Asp-Ser-Ser)6 (DSS)6	Peptides	Metabolic Disease
(Asp-Ser-Ser)6 ((DSS)6) is an artificially designed bone-targeting peptide. (Asp-Ser-Ser)6 is used as a ligand to modify apoptotic extracellular vesicles (ApoEVs) in order to enhance the bone targeting and efficacy of ApoEVs in the treatment of osteoporosis. (Asp-Ser-Ser)6 can be used for research on osteoporosis .

Cat. No.	Product Name	Target	Research Area	Image

HY-108786

Asfotase alfa ENB-0040	Phosphatase	Metabolic Disease
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ^/ knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.